Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held in New York from September 8-10, 2025.

Armata's presentation is scheduled for Wednesday, September 10, from 1:30- 2:00 PM ET .

To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for  Pseudomonas aeruginosa, Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization.

Media Contacts:

At Armata:

Pierre Kyme

ir@armatapharma.com

310-594-7035

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569

View original content to download multimedia: https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302540984.html

SOURCE Armata Pharmaceuticals, Inc.